Doximity, Inc. (DOCS)
| Market Cap | 3.65B -67.3% |
| Revenue (ttm) | 644.86M +13.1% |
| Net Income | 196.05M -12.2% |
| EPS | 0.98 -11.7% |
| Shares Out | 182.87M |
| PE Ratio | 20.35 |
| Forward PE | 13.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,475,644 |
| Open | 19.30 |
| Previous Close | 19.39 |
| Day's Range | 19.28 - 20.00 |
| 52-Week Range | 17.15 - 76.51 |
| Beta | 1.35 |
| Analysts | Buy |
| Price Target | 25.15 (+26.13%) |
| Earnings Date | May 13, 2026 |
About DOCS
Doximity, Inc. operates as a digital platform for medical professionals in the United States. Its platform provides its members with digital tools built for medicine, that enables its members to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The company primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, ... [Read more]
Financial Performance
In fiscal year 2026, Doximity's revenue was $644.86 million, an increase of 13.05% compared to the previous year's $570.40 million. Earnings were $196.05 million, a decrease of -12.16%.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for DOCS stock is "Buy." The 12-month stock price target is $25.15, which is an increase of 26.13% from the latest price.
News
Doximity to Present at the William Blair 46th Annual Growth Stock Conference
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Jeff Tangney, co-founder and CEO, will present at the Wil...
Cisco upgraded, Doximity downgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by…
Doximity downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Doximity (DOCS) to Equal Weight from Overweight with a $20 price target
Barclays downgrades Doximity on slowing industry growth
Barclays downgraded Doximity (DOCS) to Equal Weight from Overweight with a price target of $20, down from $38. Growth in the digital advertising space is slowing while competition is ramping,…
Starbucks upgraded, Doximity downgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by…
Why Is Doximity Stock (DOCS) Falling Today, 5/14/26?
Doximity ($DOCS) shares fell 24% after the company posted mixed Q4 results and issued a weaker outlook for FY2027, which led several analysts to cut their ratings. The sell-off reflects…
Doximity price target lowered to $19 from $29 at Truist
Truist analyst Jailendra Singh lowered the firm’s price target on Doximity (DOCS) to $19 from $29 and keeps a Hold rating on the shares after the company’s Q1 results and…
Doximity price target lowered to $30 from $34 at Canaccord
Canaccord lowered the firm’s price target on Doximity (DOCS) to $30 from $34 and keeps a Buy rating on the shares. The firm said their buy thesis remains intact as…
Doximity price target lowered to $26 from $34 at Mizuho
Mizuho lowered the firm’s price target on Doximity (DOCS) to $26 from $34 and keeps a Neutral rating on the shares. The firm sees the company’s “more muted” fiscal 2027…
Doximity price target lowered to $27 from $55 at Needham
Needham analyst Scott Berg lowered the firm’s price target on Doximity (DOCS) to $27 from $55 and keeps a Buy rating on the shares after its Q4 earnings miss. The…
Doximity price target lowered to $28 from $33 at JPMorgan
JPMorgan lowered the firm’s price target on Doximity (DOCS) to $28 from $33 and keeps a Neutral rating on the shares.
Doximity price target lowered to $20 from $25 at BMO Capital
BMO Capital analyst Sean Dodge lowered the firm’s price target on Doximity (DOCS) to $20 from $25 and keeps a Market Perform rating on the shares. The company’s Q4 results…
Doximity price target lowered to $35 from $49 at Morgan Stanley
Morgan Stanley analyst Craig Hettenbach lowered the firm’s price target on Doximity (DOCS) to $35 from $49 and keeps an Overweight rating on the shares. Doximity posted a modest beat…
Doximity price target lowered to $24 from $28 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Doximity (DOCS) to $24 from $28 and keeps a Neutral rating on the shares. Doximity delivered results above expectations but showed further…
Doximity plunges 24% on weak guidance, analysts slash PTs on increased AI spending
Shares of Doximity (NYSE: DOCS) plunged on Thursday after the telehealth platform reported weaker-than-expected quarterly profit and issued fiscal 2027 revenue guidance that fell significantly short o...
Doximity price target lowered to $25 from $31 at Leerink
Leerink analyst Michael Cherny lowered the firm’s price target on Doximity (DOCS) to $25 from $31 and keeps an Outperform rating on the shares.
Doximity downgraded to Neutral from Buy at BTIG
BTIG downgraded Doximity (DOCS) to Neutral from Buy without a price target following the earnings report. The company’s fiscal 2027 guidance came in well below expectations, the analyst tells investor...
Doximity Q4 Earnings Call Highlights
Doximity NYSE: DOCS reported fiscal fourth-quarter revenue above the high end of its guidance and said it is entering what management called an “AI investment year,” with higher spending planned for a...
Doximity Earnings Call Transcript: Q4 2026
Q4 and full-year results exceeded guidance, with strong free cash flow and accelerating AI engagement. FY27 guidance reflects modest revenue growth and continued AI investment, with minimal near-term AI revenue but strong long-term potential.
Doximity Earnings release: Q4 2026
Doximity released its Q4 2026 earnings on May 13, 2026, summarizing the period's financial results.
Doximity Annual report: Q4 2026
Doximity has published its Q4 2026 annual report on May 13, 2026.
Doximity Partners with Aledade to Bring Clinical AI to Value-Based Care Settings
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced an integration with Aledade, a physician‑led, national leader ...
Doximity Announces Fourth Quarter and Fiscal Year 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 fourth quarter and fiscal year ende...